Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

NCT07677891 on ClinicalTrials.gov · last registry update 2026-07-01

Registered but not yet open, with 60 participants planned. Due to report May 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Change in HbA1c from Baseline at Week 32. Sponsors move these dates routinely; any movement since this site started watching is listed below. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: ProGen. Co., Ltd.
Sponsor type: Other
Enrollment: 60
Started: 2026-10
Primary completion: 2027-05 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c from Baseline at Week 32

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.